WEN-JEN HWU to Cancer Vaccines
This is a "connection" page, showing publications WEN-JEN HWU has written about Cancer Vaccines.
Connection Strength
0.350
-
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003 Nov 01; 9(14):5214-20.
Score: 0.157
-
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
Score: 0.076
-
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20; 25(15):2078-85.
Score: 0.050
-
A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine. 2004 Jul 29; 22(21-22):2904-9.
Score: 0.041
-
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77.
Score: 0.015
-
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res. 2004 Jul 15; 10(14):4717-23.
Score: 0.010